Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 2, 2012, Pages 47-50

  Rostami Hodjegan, Amin ^a   Tamai, Ikumi ^b   Pang, K Sandy ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

XENOBIOTIC AGENT;

COMPUTER PROGRAM; DRUG BINDING; DRUG DESIGN; DRUG INDUSTRY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; METHODOLOGY; MODEL; NONHUMAN; NOTE; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING;

ANIMALS; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHYSIOLOGICAL PHENOMENA;

EID: 84858697961     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1776     Document Type: Note

References (9)

1. Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259-267.
2. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth 2011; 21: 291-301.
3. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
4. Bouzom F, Ball K, Perdaems N, Walther B. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos 2012; 55-71.
5. Chen Y, Jin JY, Mukadam S, Malhi V, Kenny JR. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos 2012; 85-98.
6. Shaffer CL, Scialis RJ, Rong H, Obach RS. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. Biopharm Drug Dispos 2012; 72-84.
7. Sinha VK, Snoeys J, Van Osselaer N, Van Peer A, Mackie C, Heald D. From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in industrial setting: a workflow by using case example. Biopharm Drug Dispos 2012; 111-121.
8. Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 2012; 91: 542-549.
9. Grillo JA, Zhao P, Bullock J, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario with rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos 2012; 99-110.